382185 HDAC Inhibitor XXII, NCH51 - CAS 848354-66-5 - Calbiochem

382185
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₂₀H₂₆N₂O₂S₂ 848354-66-5

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      382185-2MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Glass bottle 2 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable S-isobutyryl prodrug that is processed intracellularly to form the potent HDAC inhibitor NCH-31 (IC50 = 48 and 170 nM, respectively, using partially purified HDAC1 or HeLa nuclear extract) that is predicted to exhibit a similar HADC binding mode as that of SAHA with its sulfhydryl replacing SAHA's hydroxamate as the active-site zinc-targeting group. NCH-51 is shown to exhibit comparable antiproliferative (mean IC50 = 3.8 µM vs. 3.7 µM for SAHA; 48 h treatment) and apoptotic activity as SAHA against various cancer cell lines, but not PBMCs from 4 healthy individuals (IC50 >30 µM with either drug), and the antioxidant N-Acetyl-L-Cysteine (NAC; Cat. No. 106425) at 2 mM is reported to abolish the cell-growth inhibition caused by either 3 µM NCH-51 or SAHA in the Multiple Myeloma U266 cultures. Half-life in human plasma at 37 °C = 24 h.
          Catalogue Number382185
          Brand Family Calbiochem®
          SynonymsThioisobutyric acid (S-(6-(4-phenyl-2-thiazolylcarbamoyl)hexyl) ester
          References
          ReferencesSanda, T., et al. 2007. Leukemia 21, 2344.
          Suzuki, T., et al. 2007. Bioorg. Med. Chem. Lett. 17, 1558.
          Suzuki, T., et al. 2005. J. Med. Chem. 48, 1019.
          Product Information
          CAS number848354-66-5
          FormWhite powder
          Hill FormulaC₂₀H₂₆N₂O₂S₂
          Chemical formulaC₂₀H₂₆N₂O₂S₂
          Structure formula ImageStructure formula Image
          Applications
          Application Comments#31: Thiol - 7-Mercaptoheptanoic acid (4-phenyl-2-thiazolyl)amide
          Biological Information
          Purity≥97% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped with Blue Ice or with Dry Ice
          Toxicity Regulatory Review
          Storage -20°C
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          382185

          References

          Reference overview
          Sanda, T., et al. 2007. Leukemia 21, 2344.
          Suzuki, T., et al. 2007. Bioorg. Med. Chem. Lett. 17, 1558.
          Suzuki, T., et al. 2005. J. Med. Chem. 48, 1019.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision14-November-2011 RFH
          SynonymsThioisobutyric acid (S-(6-(4-phenyl-2-thiazolylcarbamoyl)hexyl) ester
          DescriptionA cell-permeable S-isobutyryl prodrug that is processed intracellularly to form the potent HDAC inhibitor NCH-31 (IC50 = 48 and 170 nM, respectively, using partially purified HDAC1 or HeLa nuclear extract) that is predicted to exhibit a similar HADC binding mode as that of SAHA with its sulfhydryl replacing SAHA's hydroxamate as the active-site zinc-targeting group. NCH-51 is shown to exhibit comparable antiproliferative (mean IC50 = 3.8 µM vs. 3.7 µM for SAHA; 48 h treatment) and apoptotic activity as SAHA against various cancer cell lines, but not PBMCs from 4 healthy individuals (IC50 >30 µM with either drug), and the antioxidant N-Acetyl-L-Cysteine (NAC; Cat. No. 106425) at 2 mM is reported to abolish the cell-growth inhibition caused by either 3 µM NCH-51 or SAHA in the Multiple Myeloma U266 cultures. Half-life in human plasma at 37 °C = 24 h.
          FormWhite powder
          CAS number848354-66-5
          Chemical formulaC₂₀H₂₆N₂O₂S₂
          Structure formulaStructure formula
          Purity≥97% by HPLC
          SolubilityDMSO (100 mg/ml)
          Comments#31: Thiol - 7-Mercaptoheptanoic acid (4-phenyl-2-thiazolyl)amide
          Storage -20°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Regulatory Review
          ReferencesSanda, T., et al. 2007. Leukemia 21, 2344.
          Suzuki, T., et al. 2007. Bioorg. Med. Chem. Lett. 17, 1558.
          Suzuki, T., et al. 2005. J. Med. Chem. 48, 1019.